FDA Considers Easier Path for Certain Cancer-Linked Tests
Published Date: 6/11/2025
Proposed Rule
Summary
The FDA wants to change the rules for certain cancer test systems called in situ hybridization (ISH) tests. These tests will move from a strict approval process to a simpler one with special safety rules, making it easier and faster for companies to get them to doctors and patients. Labs and companies using or making these tests should get ready to comment by August 11, 2025, and expect new rules soon that could save time and money.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
Manufacturers: Shift from PMA to 510(k)
The FDA proposes to reclassify certain in situ hybridization (ISH) oncology test systems from class III (requiring a premarket approval (PMA)) into class II, so manufacturers would submit a premarket notification (510(k)) instead of a PMA. The rule says the 510(k) pathway is generally less burdensome and more cost-effective and typically results in a shorter review timeline compared to a PMA.
Patients: Potentially faster, wider access to ISH tests
FDA states the reclassification may provide more timely access to these ISH oncology tests and could enable more manufacturers to develop them so patients benefit from increased access to appropriately safe and effective tests. The proposal says this change could result in shorter premarket review timelines and increased availability of these tests.
Special controls to reduce false test risks
FDA proposes specific 'special controls' for these ISH oncology test systems to address risks the Agency identified—such as false positive or false negative results, failures to perform as intended, and incorrect interpretation of results—so that these devices, with special controls plus general controls, provide reasonable assurance of safety and effectiveness.
Manufacturers: Use of Predetermined Change Control Plans
FDA notes manufacturers may use Predetermined Change Control Plans (PCCPs) to implement certain future device modifications without submitting a new 510(k) for each significant change, if the PCCP is reviewed and authorized by FDA under section 515C of the FD&C Act.
510(k) submissions will still be required
FDA explicitly states it does not intend to exempt these proposed class II ISH devices from premarket notification; if the order is finalized, persons intending to market these devices must submit a 510(k) and receive clearance before marketing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-10548, Air Plan Approval; West Virginia; 2024 Amendments to West Virginia's Ambient Air Quality Standards
The EPA is proposing to approve West Virginia’s updated air quality rules for 2024, which align state standards with national clean air goals. This affects anyone living or working in West Virginia by helping keep the air cleaner and healthier. Comments on this plan are open until July 11, 2025, with no new costs expected for businesses or residents.
Next: 2025-10477, Lower 37 GHz Band and Use of Spectrum Bands Above 24 GHz for Mobile Radio Service
The FCC is asking for feedback on new rules to tighten emissions limits for super-high-frequency mobile signals above 37 GHz and improve how different users share this spectrum. They’re also fixing a technical error and exploring smarter ways to manage these airwaves. If you’re a company using or planning to use these frequencies, get ready to weigh in by mid-July 2025—this could affect how you operate and invest in future tech.